Product Details
| Product Name:
IMS2186 |
CAS No.:
1031206-36-6 |
| Purity:
99.96% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | IMS2186 |
| Description | IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2/M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity. |
| In vitro | IMS2186 (0.3-10 μM; 22 h) inhibits the proliferation of human fibroblasts and human cancer cells with IC50 values of 1.0-3.0 μM and 0.3-3.0 μM, respectively. IMS2186 (0-10 μM; 22 h) also inhibits endothelium formation with an IC50 of 0.1-0.3 μM under 10 ng/mL VEGF stimulation. Additionally, IMS2186 (0.1-10 μM; 24 h) inhibits the production of pro-inflammatory cytokines PGE2/TNF-a in macrophages with an IC50 of 0.3-1 μM, and it inhibits macrophage migration with an IC50 of 1 μM within 1.5 hours[1]. |
| In vivo | IMS2186 (2.5 mg in 0.5 mL; vitreous injection; single dose) was administered to rabbit eyes with no ocular toxicity, and IMS2186 (100 μg/eye, i.e. 50 μg/μL solution dosage 2.0 μL; single dose) exhibited an anti-proliferative effect on the rat model of laser-induced choroidal neovascularization (CNV) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (202.48 mM), Sonication is recommended.
|
| Keywords | IMS-2186 | IMS2186 | IMS 2186 |
| Inhibitors Related | Ribociclib | Regorafenib monohydrate | Sorafenib | glycine | Nintedanib esylate | Regorafenib | Ethyl cinnamate | Chloramphenicol | Thymoquinone | Lenvatinib | Pazopanib | Albendazole |
| Related Compound Libraries | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
![[Orn8]-Urotensin II acetate](https://img.chemicalbook.com/ProductImageEN2/2025-10/Large/22172adf-2c10-44ec-8458-1b0ee6154077.png)
United States